a combination of amikacin and ceftazidime was used as initial empiric therapy for the treatment of 25 evaluable febrile episodes ( temperature greater than or equal to 38.5 degrees c ) in leukopenic adult patients ( wbc less than or equal to 1,000/mm3 ) with solid tumors , characterized by poor prognosis because of low performance status ( median karnofsky score : 50 ) and progressive disease ( 76 % of cases ) .
C0007559
ceftazidime
C0015967
febrile